MARKET

GERN

GERN

Geron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.300
+0.060
+4.84%
After Hours: 1.285 -0.015 -1.15% 16:09 07/28 EDT
OPEN
1.250
PREV CLOSE
1.240
HIGH
1.300
LOW
1.230
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
2.355
52 WEEK LOW
1.220
MARKET CAP
414.14M
P/E (TTM)
-4.5423
1D
5D
1M
3M
1Y
5Y
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the ...
Business Wire · 5d ago
Return On Capital Employed Overview: Geron
During Q1, Geron's (NASDAQ:GERN) reported sales totaled $137.00 thousand. Despite a 22.3% in earnings, the company posted a loss of $28.45 million. Geron collected $50.00 thousand in revenue during Q4, but reported earnings showed a $23.27 million loss.
Benzinga · 06/24 13:49
Thinking about buying stock in ContextLogic, Adial Pharmaceuticals, Geron Corp, Orphazyme, or Citius Pharmaceuticals?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, ADIL, GERN, ORPH, and CTXR.
PR Newswire - PRF · 06/22 14:45
Geron (GERN) Soars on Imetelstat Data for Myelofibrosis
Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.
Zacks · 06/21 16:15
Thinking about buying stock in Geron Corp, Ashford Hospitality Trust, Paratek Pharmaceuticals, Seanergy Maritime, or TAL Education?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GERN, AHT, PRTK, SHIP, and TAL.
PR Newswire - PRF · 06/21 14:55
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Zacks · 06/21 12:36
MicroStrategy, Marathon Digital among premarket losers' pack
Immutep (IMMP) -14% after expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and anti-PD-1 therapyAshford Hospitality Trust (AHT) -10% after inks stock purchase agreement with Seven Knots.BIT Mining (BTCM)
Seekingalpha · 06/21 12:19
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 06/21 12:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GERN. Analyze the recent business situations of Geron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GERN stock price target is 4.200 with a high estimate of 7.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 205
Institutional Holdings: 146.45M
% Owned: 45.97%
Shares Outstanding: 318.57M
TypeInstitutionsShares
Increased
51
9.18M
New
18
2.37M
Decreased
39
7.34M
Sold Out
22
35.76M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.42%
Pharmaceuticals & Medical Research
+1.82%
Key Executives
Chairman/President/Chief Executive Officer/Director
John Scarlett
Chief Financial Officer/Executive Vice President - Finance/Treasurer
Olivia Bloom
Chief Operating Officer/Executive Vice President
Andrew Grethlein
Executive Vice President/Secretary
Stephen Rosenfield
Executive Vice President
Anil Kapur
Executive Vice President
Melissa Kelly Behrs
Executive Vice President
Aleksandra Rizo
Lead Director/Independent Director
Karin Eastham
Independent Director
Dawn Bir
Independent Director
V. Bryan Lawlis
Independent Director
Susan Molineaux
Independent Director
Elizabeth O'Farrell
Independent Director
Robert Spiegel
No Data
About GERN
Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.